1-2 of 2
Hsiaoyin Charlene Mao
Close
Sort by
Journal Articles

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2 -mutant AML

Clinical Trials & Observations
Sheng F. Cai, Ying Huang, Jennie R. Lance, Hsiaoyin Charlene Mao, Andrew J. Dunbar, Samantha N. McNulty, Todd Druley, Yan Li, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark Litzow, Tara Lin, Prapti Patel, Matthew C. Foster, Michael Boyiadzis, Robert H. Collins, Jordan Chervin, Abigail Shoben, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Timothy L. Chen, Ashley O. Yocum, Franchesca Druggan, Sonja Marcus, Mona Stefanos, Brian J. Druker, Alice S. Mims, Uma Borate, Amy Burd, John C. Byrd, Ross L. Levine, Eytan M. Stein
Journal: Blood Advances
Blood Adv (2024) 8 (2): 429–440.
https://doi.org/10.1182/bloodadvances.2023010563
Published: 2024
Includes: Supplemental data
Journal Articles

Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma

Bethany Mundy-Bosse, Nathan Denlinger, Eric McLaughlin, Nitin Chakravarti, Susan Hwang, Li Chen, Hsiaoyin Charlene Mao, David Kline, Youssef Youssef, Rebecca Kohnken, Dean Anthony Lee, Gerard Lozanski, Aharon G. Freud, Pierluigi Porcu, Basem William, Michael A. Caligiuri, Anjali Mishra
Journal: Blood Advances
Blood Adv (2018) 2 (15): 1818–1827.
https://doi.org/10.1182/bloodadvances.2018020388
Published: 2018
Includes: Supplemental data